```html

Yaws (Early) Skin Lesions – Comprehensive Medical Guide

Overview

Yaws is a chronic, contagious skin disease caused by the bacterium Trepallia pallidum subspecies pertenue. It belongs to the same family of spirochetes that cause syphilis, but it is transmitted only by direct skin‑to‑skin contact, not sexually. Yaws primarily affects children living in remote, rural tropical regions where sanitation is poor.

• Geographic focus: Historically widespread in Africa, Southeast Asia, the Pacific Islands, and parts of the Americas. As of 2023, the World Health Organization (WHO) estimates about 80,000–100,000 active cases remain, concentrated in 13 endemic countries (e.g., Ghana, Papua New Guinea, Tanzania).
• Age group:  ~80 % of cases occur in children aged 5–15 years.
• Gender: Slight male predominance, but infection rates are similar between sexes.
• Transmission: Non‑sexual skin contact with the fluid from early papillomatous or ulcerative lesions; the organism can survive for several days in a warm, humid environment.

Yaws progresses through three clinical stages—early (primary & secondary), latent, and late (tertiary). This guide focuses on the **early skin lesions** that appear during the first 6 months of infection.

Symptoms

Early yaws presents a spectrum of skin findings that may appear singly or in clusters. The lesions evolve quickly, often within days.

Primary (Initial) Lesion – “Mother‑Rose” Nodule

• Appearance: A painless, raised papule (1–2 cm) with a reddish‑brown base that later becomes a **hyperkeratotic crust** resembling a rosebud.
• Location: Usually on the limbs (feet, ankles, calves) but can appear on the trunk or face.
• Course: Softens and ulcerates within 1–2 weeks, then heals spontaneously, leaving a flat scar.

Secondary (Disseminated) Lesions

• Papillomatous warty lesions: Small, moist, creamy‑white or pink papules that may coalesce into larger plaques. Common on the arms, legs, and buttocks.
• Ulcerative lesions: Shallow, flat‑topped ulcers with serous or serosanguinous exudate; edges are well‑defined and may have a yellow‑white crust.
• Rash: Diffuse erythematous macules or patches, sometimes with a fine scaling surface.
• Associated symptoms: Low‑grade fever, malaise, swollen lymph nodes (especially inguinal or cervical), and mild joint pain.

General Signs

• Lesions are **non‑painful** unless secondarily infected.
• Swelling of the surrounding tissue may give a “honey‑comb” appearance.
• Systemic signs are usually mild; severe constitutional symptoms are uncommon.

Causes and Risk Factors

Cause

The disease is caused by Treponema pallidum subspecies pertenue, a spiral‑shaped bacterium that penetrates the epidermis through minor skin abrasions. Once inside, it multiplies locally, producing the characteristic lesions.

Risk Factors

• Living in endemic rural settings with limited access to clean water and health services.
• Close contact with infected children playing barefoot or sharing communal sleeping areas.
• Poor personal hygiene – frequent skin maceration from sweating or mud.
• Warm, humid climate that favors bacterial survival outside the host.
• Travel or migration to endemic regions without prior exposure or immunity.

Diagnosis

Accurate diagnosis combines clinical assessment with laboratory testing.

Clinical Evaluation

• Detailed history of exposure, travel, and lesion evolution.
• Physical exam focusing on the morphology, distribution, and stage of lesions.

Laboratory Tests

• Dark‑field microscopy: Direct visualization of spirochetes from lesion exudate. Highly specific but requires expertise.
• Serologic tests:
  • Non‑treponemal tests (RPR, VDRL) – detect antibodies to cardiolipin; become positive 1–2 weeks after infection.
  • Treponemal tests (TPPA, FTA‑ABS) – remain positive for life, confirming exposure to any treponemal species.

  Because yaws and syphilis share serologic cross‑reactivity, a positive result must be interpreted with epidemiologic context.

• Polymerase Chain Reaction (PCR): Detects *T. pallidum* DNA from lesion swabs; increasingly used in research settings and reference labs.
• Histopathology (rarely needed): Shows a superficial perivascular infiltrate with plasma cells and spirochetes on special stains.

Diagnostic Criteria (WHO)

1. Presence of a typical primary or secondary lesion in a resident of or traveler to an endemic area.
2. Positive serology (RPR ≥ 1:4 or TPPA ≥ 1:160) or direct detection of spirochetes.
3. Exclusion of other ulcerative skin diseases (e.g., tropical ulcer, impetigo).

Treatment Options

Effective therapy is simple, inexpensive, and widely available.

First‑Line Antimicrobial

• Azithromycin 30 mg/kg (single oral dose, max 2 g) – recommended by WHO for community‑wide mass treatment campaigns.
• Benzathine penicillin G 2.4 MU IM single dose – alternative for patients with azithromycin contraindication or in settings where azithromycin resistance is documented.

Both regimens achieve >95 % cure rates for early lesions (< 6 months) when administered correctly (Mayo Clinic, 2022).

Alternative Regimens

• Doxycycline 100 mg orally twice daily for 14 days (for children >8 years and non‑pregnant adults).
• Erythromycin or clarithromycin in case of macrolide intolerance.

Adjunctive Care

• Clean the lesions with mild antiseptic (e.g., povidone‑iodine) to prevent secondary bacterial infection.
• Topical antibiotic ointments (e.g., mupirocin) if signs of superinfection appear.
• Pain control with acetaminophen or ibuprofen if discomfort is present.

Follow‑up

Repeat serologic testing (RPR) 3 months after treatment; a four‑fold decline in titer indicates successful therapy. Persistent or rising titers require re‑evaluation for treatment failure or reinfection.

Living with Yaws (early) skin lesions

While treatment is short, patients may need practical guidance for daily life during the active phase.

• Hygiene: Gently wash lesions daily with mild soap and water; pat dry, avoiding vigorous rubbing.
• Clothing: Wear clean, breathable cotton garments. Change socks and underwear daily to keep the skin dry.
• Foot care: Keep feet clean, trim nails, and wear protective shoes when outdoors to reduce new inoculation.
• School attendance: Children can attend school after receiving treatment; however, avoid sharing towels or clothing until lesions are fully covered or healed.
• Nutrition: A balanced diet rich in protein and vitamins (A, C, zinc) supports skin healing.
• Monitoring: Keep a simple diary of lesion size, appearance, and any new symptoms; bring this to follow‑up visits.

Prevention

Because yaws spreads through direct skin contact, community‑level measures are most effective.

• Mass drug administration (MDA): WHO recommends yearly azithromycin MDA in hyper‑endemic villages until prevalence falls below 1 %.
• Personal protective behavior: Encourage children to wear shoes, avoid walking barefoot in wet soil, and wash hands after playing.
• Environmental hygiene: Maintain clean play areas, reduce standing water that promotes skin maceration.
• Screening of contacts: Identify and treat household members and classmates of a confirmed case.
• Health education: Community outreach using local languages to explain the disease’s non‑sexual transmission.

Complications

If early lesions are left untreated, progression to latent or tertiary disease can occur, often decades later.

• Late (tertiary) yaws: Destructive gummatous lesions of bone, cartilage, and soft tissue leading to disfigurement, joint contractures, and functional disability.
• Neurologic involvement: Rare, but may cause peripheral neuropathy or meningitis.
• Secondary bacterial infection: Impetigo or cellulitis, which can spread systemically if not managed.
• Social stigma: Visible skin lesions may lead to bullying or exclusion, especially in school settings.

When to Seek Emergency Care

---

Sources: Mayo Clinic. “Yaws.” 2022; World Health Organization. “Yaws – Global Eradication Programme.” 2023; Centers for Disease Control and Prevention. “Treponemal Diseases.” 2022; Cleveland Clinic. “Treponema pallidum infections.” 2021; NIH National Library of Medicine, PubMed articles on azithromycin efficacy (2020‑2023).

```